Side-effects of 'turning point' Alzheimer's drug donanemab as disease slowed in clinical trial
A major clinical trial of the Eli Lilly drug has taken place.
Full Article
Side-effects of 'turning point' Alzheimer's drug donanemab as disease slowed in clinical trial
Tamworth Herald
0 shares
1 views
You might like
Related news coverage
Government To Consider Alternatives To Patent Monopoly Financing Of Drug Development – Analysis
Eurasia Review
In some really big news that is likely to get almost no media attention, Senator Bernie Sanders, the chair of the Senate HELP..
-
Drug shows promise in slowing effects of Alzheimer's disease
Newsy
-
Trial shows new drug can slow down Alzheimer’s significantly
Upworthy
-
Treating Alzheimer’s Very Early Offers Better Hope of Slowing Decline, Study Finds
Upworthy
-
Experimental Eli Lilly drug slows Alzheimer’s by 60% for mildly impaired patients in trial
Upworthy
Advertisement
More coverage
Alzheimer's could be 'treated like asthma or diabetes' thanks to new drug that slows disease
Donanemab was found to slow “clinical decline” by up to 35%, meaning that people with disease could still go about performing..
Daily Record
FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval
Today, the U.S. Food and Drug Administration converted Leqembi (lecanemab-irmb), indicated to treat adult patients with..
Upworthy